Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
52 participants
INTERVENTIONAL
2017-01-01
2019-07-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Remote Controlled Analgesia on Patient Experience
NCT02720965
Ultrasound-assisted Versus Real-time Ultrasound-guided Combined Spinal-epidural Anesthesia in Elderly Patients
NCT06241716
Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)
NCT06452147
Postoperative Patient-controlled Perineural Analgesia After Orthopedic Surgery by "Remote Control" Versus "Bedside Care"
NCT02018068
Algorithm of Muscle Function Tests to Detect Residual Neuromuscular Blockade.
NCT03219138
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Statistical analysis was performed using SPSS STATISTICS software version 23. Absolute and percentage frequencies were calculated for qualitative variables. And mean, standard deviation and interquartile range for quantitative variables. The normality of the quantitative variables was assessed by the Shapiro-Wilk test. The chi-square test was used to assess the difference in the incidence of catheterization in the two groups and the incidence of nausea and vomiting in 24 hours. To evaluate the difference in the mean time to urination, even after sounding, the Student's t test for independent samples was used. Doses of codeine and morphine at 24 hours and assessment of pain on movement and rest at 12 and 24 hours (by the visual analog scale of pain) were assessed by the Mann Whitney test.
P \<0.05 was considered statistically significant. The 52 patients included in the survey were allocated randomly to one of the study groups. Randomization was performed immediately before the interventions studied using the electronic random allocation application Randomizer for Clinical Trial for iPad / iPhone, developed by the company Medsharing (http://www.ecrfmedsharing.com/iphone\_ipad\_randomization.php).
All patients received spinal anesthesia. The technique included sterile preparation of the puncture site at the L3-L4 or L4-L5 level using Whitacre 27G or 25G needles. Group 1 patients received subarachnoid block with 20 mg of hyperbaric bupivacaine + 200 mcg of morphine and group 2 patients received subarachnoid block with 20 mg of hyperbaric bupivacaine and peripheral nerve block.Peripheral nerve blocks were performed after spinal anesthesia, before the start of the surgical procedure under ultrasound visualization associated with the use of neurostimulator. The choice of the nerve to be blocked was based on the innervation related to analgesia of the surgical site: femoral nerve block or sciatic nerve.
In the post-anesthetic care unit, the following parameters were assessed:
* Need for bladder catheterization;
* Time for spontaneous urination (time in minutes between subarachnoid block and spontaneous urination);
* Presence of pain and the need to use opioids;
* Presence of nausea / vomiting and the need to use antiemetics.
Patients were evaluated at 12 and 24 hours after the surgical procedure for:
* Need for bladder catheterization;
* Time for the first spontaneous urination (with or without previous relief bladder catheter);
* Presence of nausea / vomiting;
* Pain assessment by analogue-visual scale from 0 to 10, at the operated site, at rest and during movement;
* Need to use opioids, noting which opioid and dose used.
The postoperative prescription was standardized:
* Paracetamol 500 mg orally 6/6 hours fixed;
* Dipyrone 1 g intravenous 6/6 hours fixed;
* Codeine 30 mg orally 6/6 hours, if mild to moderate pain using an analogue-visual scale (1 to 6);
* Morphine 3 mg intravenously up to 3/3 hours, if severe pain by analogue-visual scale (7 to 10);
* Ondasentron 4 mg intravenously up to 8/8 hours, if nausea / vomiting is present.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
spinal anesthesia with morphine
This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine + 200 mcg of Morphine
spinal anesthesia with morphine
spinal anesthesia without morphine + peripheral nerve block
This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine and peripheral nerve block with 0.2 to 0.375% Ropivacaine, in a volume of 20 to 30 mL.
spinal anesthesia without morphine + peripheral nerve block
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
spinal anesthesia with morphine
spinal anesthesia without morphine + peripheral nerve block
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Possibility and acceptance of performing the surgical procedure under spinal anesthesia
* Minimum hospital stay of 24 hours
* Acceptance and signature of the informed consent form
Exclusion Criteria
* Patients who did not agree with the informed consent term and / or did not sign
* Patients with a history of urological problems
* Severe cognitive disorders
* Patients who were unable to urinate spontaneously before surgery
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital de Clinicas de Porto Alegre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carolina L Schiavo, M.D, M.Sc
Role: PRINCIPAL_INVESTIGATOR
Hospital de Clinicas de Porto Alegre
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20160443
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.